Clinical Trials Browser

Interventional × elacestrant × 30 days × Clear all

NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06492616 2026-05-27

ELEGANT

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Phase 2 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT07209449 2026-05-22

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Phase 2 Recruiting

Recurrence, Endometrial Neoplasms

NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Phase 2 Recruiting

GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

NCT05512364 2026-05-15

TREAT ctDNA

Phase 3 Recruiting

Breast Neoplasms

NCT07395336 2026-05-14

COMBINE-01

Phase 2 Recruiting

Breast Neoplasms

NCT06638307 2026-05-12

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Phase 1 Recruiting

Advanced Breast Cancer

NCT06923527 2026-05-12

Circulating Tumor DNA

Phase 2 Recruiting

ER+ Breast Cancer

NCT05596409 2026-05-07

ELCIN

Phase 2 Active not recruiting

Breast Neoplasms

NCT07242352 2026-05-06

ADAPTela

Phase 3 Recruiting

Breast Neoplasms